X4 Pharmaceuticals Valuation
| XFOR Stock | USD 3.56 0.10 2.73% |
At this time, the entity appears to be undervalued. X4 Pharmaceuticals owns a latest Real Value of $4.64 per share. The recent price of the entity is $3.56. Our model calculates the value of X4 Pharmaceuticals from inspecting the entity fundamentals such as return on asset of -0.34, and Shares Owned By Insiders of 1.15 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting X4 Pharmaceuticals' valuation include:
Price Book 5.0516 | Enterprise Value | Enterprise Value Ebitda 1.1003 | Price Sales 9.1608 | Enterprise Value Revenue 7.8412 |
Undervalued
Today
Please note that X4 Pharmaceuticals' price fluctuation is relatively risky at this time. Calculation of the real value of X4 Pharmaceuticals is based on 3 months time horizon. Increasing X4 Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the XFOR stock is determined by what a typical buyer is willing to pay for full or partial control of X4 Pharmaceuticals. Since X4 Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of XFOR Stock. However, X4 Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.56 | Real 4.64 | Target 9.33 | Hype 3.55 |
The intrinsic value of X4 Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence X4 Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of X4 Pharmaceuticals helps investors to forecast how XFOR stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of X4 Pharmaceuticals more accurately as focusing exclusively on X4 Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use X4 Pharmaceuticals' intrinsic value based on its ongoing forecasts of X4 Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against X4 Pharmaceuticals' closest peers.
X4 Pharmaceuticals Cash |
|
XFOR Revenue by Product
X4 Pharmaceuticals Total Value Analysis
X4 Pharmaceuticals is at this time estimated to have valuation of 266.44 M with market capitalization of 311.27 M, debt of 78.09 M, and cash on hands of 47.38 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the X4 Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
266.44 M | 311.27 M | 78.09 M | 47.38 M |
X4 Pharmaceuticals Investor Information
About 42.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 8.92. X4 Pharmaceuticals last dividend was issued on the 14th of March 2019. The entity had 1:30 split on the 28th of April 2025. Based on the key indicators related to X4 Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, X4 Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.X4 Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. X4 Pharmaceuticals has an asset utilization ratio of 1.75 percent. This connotes that the Company is making $0.0175 for each dollar of assets. An increasing asset utilization means that X4 Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.X4 Pharmaceuticals Profitability Analysis
Based on X4 Pharmaceuticals' profitability indicators, X4 Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess X4 Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2016-03-31 | Previous Quarter -25.7 M | Current Value -29.8 M | Quarterly Volatility 21.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.91 | 0.79 |
|
|
For X4 Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of X4 Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well X4 Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between X4 Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of X4 Pharmaceuticals over time as well as its relative position and ranking within its peers.
X4 Pharmaceuticals Earnings per Share Projection vs Actual
By analyzing X4 Pharmaceuticals' earnings estimates, investors can diagnose different trends across X4 Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for X4 Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.X4 Pharmaceuticals Ownership Allocation
X4 Pharmaceuticals secures a total of 87.44 Million outstanding shares. 30% of X4 Pharmaceuticals outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Hence, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.X4 Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (37.45 M) with profit before overhead, payroll, taxes, and interest of 28.28 M.About X4 Pharmaceuticals Valuation
The stock valuation mechanism determines X4 Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of X4 Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of X4 Pharmaceuticals. We calculate exposure to X4 Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of X4 Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.6 M | 1.7 M | |
| Pretax Profit Margin | (16.70) | (17.54) | |
| Operating Profit Margin | (16.37) | (17.19) | |
| Net Loss | (16.84) | (17.69) | |
| Gross Profit Margin | 0.79 | 0.91 |
X4 Pharmaceuticals Current Valuation Indicators
X4 Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final X4 Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as X4 Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use X4 Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes X4 Pharmaceuticals' worth.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.